<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492115</url>
  </required_header>
  <id_info>
    <org_study_id>AG08415</org_study_id>
    <secondary_id>R01AG008415</secondary_id>
    <nct_id>NCT00492115</nct_id>
  </id_info>
  <brief_title>Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease</brief_title>
  <acronym>TAP</acronym>
  <official_title>Cognitive Benefits of Treating Sleep Apnea in Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with sleep disordered breathing (SDB), also called sleep apnea, experience nighttime
      disrupted sleep and, because they stop breathing for short periods during the night, do not
      get sufficient oxygen to their brains. This can frequently result in daytime impairments
      including difficulties with memory. The state-of-the-art treatment for SDB is Continuous
      Positive Airway Pressure (CPAP). Many non-demented SDB patients who are successfully treated
      with CPAP show improvement in memory and other cognitive functions. Data have shown that
      patients with Parkinson's disease have a high rate of SDB. Patients with Parkinson's disease
      also often have problems with memory. This study will test the effects of treating SDB among
      patients with Parkinson's disease and SDB. Specifically, the study will test the effect of
      CPAP treatment on SDB and sleep; the effect of CPAP treatment on daytime sleepiness,
      cognition, overall quality of life and mood; the effect of CPAP treatment on the frequency of
      symptoms of REM behavior disorder and restless legs syndrome; the effect of continued CPAP
      use (beyond the six weeks of the study) on SDB, sleep, cognition, mood and quality of life;
      whether the study-partner feels that CPAP improves the patient's sleep, mood and overall
      functioning; whether study-partners feel that their own sleep, mood and overall functioning
      improve as the patient's sleep improves both during the 6-week protocol and at follow-up for
      those opting to continue using CPAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the effect of three weeks vs. six weeks of CPAP treatment on
      cognitive functioning and sleep in patients with Parkinson's disease and sleep apnea. It is
      designed as a randomized, double blind, placebo-controlled trial of CPAP. As a comparison
      group, half the patients will first be randomly assigned to three weeks of shamCPAP, followed
      by three weeks of therapeutic CPAP treatment. Sleep, functional outcome and mood
      questionnaires and a repeatable neuropsychological test battery, chosen to be sensitive to
      the type of changes we expect to find in memory and cognitive function, will be administered
      before the start of treatment, after three weeks, and after six weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tests to Determine the Apnea-hypopnea Index (Number of Apneas and Hypopneas Per Hour of Sleep)</measure>
    <time_frame>six weeks</time_frame>
    <description>Overnight sleep studies were done to determine the effect of treatment on the apnea-hypopnea index (number of apneas and hypopneas per hour of sleep)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Stages; %Time Spent at SaO2&lt;90%;</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overnight sleep studies were done to examine the effect of CPAP treatment on sleep stages and on %time spent at Sa)2&lt;90%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Sleep Disordered Breathing</condition>
  <arm_group>
    <arm_group_label>therapeutic CPAP Treatment (6 weeks)&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention - The active comparator is an intervention of nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham CPAP/therapetuic CPAP (6 weeks)&quot;</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo comparator is an intervention of placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.
Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure (CPAP)</intervention_name>
    <description>therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks</description>
    <arm_group_label>therapeutic CPAP Treatment (6 weeks)&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo CPAP</intervention_name>
    <description>Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks</description>
    <arm_group_label>Sham CPAP/therapetuic CPAP (6 weeks)&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of dementia due to Parkinson's disease (according to the fourth
             edition of the Diagnostic and Statistical Manual of Mental Disorders (code 294.1)

          -  MMSE score between 18 and 26, inclusive; cognitive symptoms must occur at least one
             year after the diagnosis of PDD

          -  Apnea hypopnea index &gt;10 (i.e., 10 apneas plus hypopneas per hour of sleep)

          -  Over the age of 50 years

          -  Stable health

          -  Fluent English speaking

          -  Patients will be allowed to continue dopaminergic medications, acetylcholinesterase
             inhibitors, psychotropic medications, memory enhancers, health food supplements, etc.
             as long as they have been stable on the same dose for at least two months prior to
             participation and agree to continue on this dose for the duration of the 6-week study.

        Exclusion Criteria:

          -  Current treatment for sleep apnea (to avoid discontinuing already established
             treatment for sleep apnea and any carry over confounding effect of treatment on
             cognition).

          -  Central sleep apnea

          -  Use of medications known to influence sleep (i.e. sedative hypnotics, narcotics) if
             the dose cannot remain stable for the duration of the study.

          -  Bronchospastic and symptomatic chronic obstructive pulmonary disease as indicated by
             regular use of bronchodilators, steroids, history of carbon dioxide retention, waking
             hypoxemia (PaO2 &lt;60 mmHg or SpO2 &lt;92 % by pulse oximetry), or use of supplemental
             oxygen.

          -  Symptomatic coronary or cerebral vascular disease (history of myocardial infarction,
             angina, stroke, or transient ischemic attacks), history of life-threatening
             arrhythmias, cardiomyopathy, or current alcohol or drug abuse

          -  Current diagnosis of active seizure disorder; presence of any neurodegenerative
             disorder other than PDD or other causes of dementia

          -  Any behavioral or physical problem that would preclude completion of the primary
             evaluation or treatment with CPAP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Ancoli-Israel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cooke JR, Liu L, Natarajan L, He F, Marler M, Loredo JS, Corey-Bloom J, Palmer BW, Greenfield D, Ancoli-Israel S. The effect of sleep-disordered breathing on stages of sleep in patients with Alzheimer's disease. Behav Sleep Med. 2006;4(4):219-27.</citation>
    <PMID>17083302</PMID>
  </results_reference>
  <results_reference>
    <citation>Chong MS, Ayalon L, Marler M, Loredo JS, Corey-Bloom J, Palmer BW, Liu L, Ancoli-Israel S. Continuous positive airway pressure reduces subjective daytime sleepiness in patients with mild to moderate Alzheimer's disease with sleep disordered breathing. J Am Geriatr Soc. 2006 May;54(5):777-81.</citation>
    <PMID>16696743</PMID>
  </results_reference>
  <results_reference>
    <citation>Ayalon L, Ancoli-Israel S, Stepnowsky C, Marler M, Palmer BW, Liu L, Loredo JS, Corey-Bloom J, Greenfield D, Cooke J. Adherence to continuous positive airway pressure treatment in patients with Alzheimer's disease and obstructive sleep apnea. Am J Geriatr Psychiatry. 2006 Feb;14(2):176-80.</citation>
    <PMID>16473983</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>November 8, 2016</results_first_submitted>
  <results_first_submitted_qc>May 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2018</results_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sonia Ancoli-Israel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>dementia</keyword>
  <keyword>apnea</keyword>
  <keyword>memory</keyword>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were referred to UCSD by community neurologists or volunteered after hearing a talk about the study at PD support group meetings.</recruitment_details>
      <pre_assignment_details>183 contacted; 144 screened/phone; 106 consented, 5 dropped/12 excluded; 89 screened for apnea with sleep study (2 dropped during night study), 44 had no sleep apnea. 5 declined treatment.
19 participants randomized to each arm</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A: Continuous Positive Airway Pressure (CPAP)</title>
          <description>Continuous positive airway pressure (CPAP)
Continuous positive airway pressure (CPAP): therapeutic CPAP for six weeks</description>
        </group>
        <group group_id="P2">
          <title>B: Placebo Continuous Positive Airway Pressure</title>
          <description>Placebo Continuous Positive airway pressure
Placebo CPAP: Ineffective CPAP 3 weeks placebo CPAP followed by 3 weeks of therapeutic CPAP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16">3 dropped due to anxiety or not being able to tolerate CPAP</participants>
                <participants group_id="P2" count="15">4 dropped due to not being able to tolerate CPAP</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A: Continuous Positive Airway Pressure</title>
          <description>Continuous Positive Airway Pressure (therapeutic CPAP) for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>B. Sham CPAP</title>
          <description>Sham (placebo) CPAP for 3 weeks followed by therapeutic CPAP for 3 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="8.5"/>
                    <measurement group_id="B2" value="67.7" spread="10.0"/>
                    <measurement group_id="B3" value="67.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tests to Determine the Apnea-hypopnea Index (Number of Apneas and Hypopneas Per Hour of Sleep)</title>
        <description>Overnight sleep studies were done to determine the effect of treatment on the apnea-hypopnea index (number of apneas and hypopneas per hour of sleep)</description>
        <time_frame>six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Continuous Positive Airway Pressure (CPAP):</title>
            <description>CPAP
Continuous positive airway pressure (CPAP): therapeutic CPAP</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo CPAP: Ineffective CPAP</title>
            <description>Placebo CPAP
Placebo CPAP: Ineffective CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Tests to Determine the Apnea-hypopnea Index (Number of Apneas and Hypopneas Per Hour of Sleep)</title>
          <description>Overnight sleep studies were done to determine the effect of treatment on the apnea-hypopnea index (number of apneas and hypopneas per hour of sleep)</description>
          <units>apnea hypopnea index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2"/>
                    <measurement group_id="O2" value="20" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Stages; %Time Spent at SaO2&lt;90%;</title>
        <description>Overnight sleep studies were done to examine the effect of CPAP treatment on sleep stages and on %time spent at Sa)2&lt;90%.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Continuous Positive Airway Pressure (CPAP):</title>
            <description>CPAP
Continuous positive airway pressure (CPAP): therapeutic CPAP</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo CPAP: Ineffective CPAP</title>
            <description>Placebo CPAP
Placebo CPAP: Ineffective CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Stages; %Time Spent at SaO2&lt;90%;</title>
          <description>Overnight sleep studies were done to examine the effect of CPAP treatment on sleep stages and on %time spent at Sa)2&lt;90%.</description>
          <units>Percent time spent at low oxygen &lt;90%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1"/>
                    <measurement group_id="O2" value="12.9" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the full 6 weeks per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A: Continuous Positive Airway Pressure (CPAP): Therapeutic CPA</title>
          <description>CPAP
Continuous positive airway pressure (CPAP): therapeutic CPAP for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>B: Placebo CPAP: Ineffective CPAP</title>
          <description>Placebo CPAP
Placebo CPAP: Ineffective CPAP for 3 weeks followed by therapeutic CPAP for 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sonia Ancoli-Israel</name_or_title>
      <organization>UCSD</organization>
      <phone>858 822 7710</phone>
      <email>sancoliisrael@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

